Get the Stockscreener App
8.92
1.83%
0.16
After Hours:
9.10
0.18
+2.02%
Regenxbio Inc stock is traded at $8.92, with a volume of 357.36K.
It is up +1.83% in the last 24 hours and down -8.23% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$8.76
Open:
$8.7
24h Volume:
357.36K
Relative Volume:
0.78
Market Cap:
$440.85M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.4114
EPS:
-6.32
Net Cash Flow:
$-194.72M
1W Performance:
-1.55%
1M Performance:
-8.23%
6M Performance:
-47.00%
1Y Performance:
-41.81%
1-Day Range:
$8.58
$8.97
1-Week Range:
$8.535
$9.27
52-Week Range:
$8.535
$28.80
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Regenxbio Inc Holdin - GuruFocus.com
Sorrento Therapeutics (OTCMKTS:SRNEQ) & REGENXBIO (NASDAQ:RGNX) Financial Survey - Defense World
REGENXBIO to Participate in Upcoming Investor Conferences - StockTitan
When (RGNX) Moves Investors should Listen - Stock Traders Daily
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO (RGNX) to Release Quarterly Earnings on Wednesday - MarketBeat
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - StockTitan
Assenagon Asset Management S.A. Lowers Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
RGNX stock touches 52-week low at $9.1 amid market challenges By Investing.com - Investing.com South Africa
RGNX stock touches 52-week low at $9.1 amid market challenges - Investing.com
SG Americas Securities LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
How the (RGNX) price action is used to our Advantage - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Rating Reiterated by Chardan Capital - Defense World
The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - MarketBeat
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting - Citizentribune
REGENXBIO (NASDAQ:RGNX) Trading Down 6.4%Time to Sell? - MarketBeat
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 - Citizentribune
ABBV-RGX-314 shows promise in wet AMD treatment By Investing.com - Investing.com UK
JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc - Yahoo Finance
Investors in REGENXBIO (NASDAQ:RGNX) from five years ago are still down 72%, even after 16% gain this past week - Simply Wall St
REGENXBIO (NASDAQ:RGNX) Stock Price Up 6.6%Should You Buy? - MarketBeat
Regenxbio Inc [RGNX] Insider Activity: An Update for Investors - Knox Daily
Millennium Management LLC Has $3.59 Million Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
(RGNX) On The My Stocks Page - Stock Traders Daily
Raymond James resumes coverage on Regenxbio stock with Outperform rating - Investing.com India
What 4 Analyst Ratings Have To Say About Regenxbio - Benzinga
REGENXBIO (NASDAQ:RGNX) Rating Reiterated by Raymond James - MarketBeat
RGNX stock touches 52-week low at $9.28 amid market challenges By Investing.com - Investing.com South Africa
RGNX stock touches 52-week low at $9.28 amid market challenges - Investing.com
REGENXBIO releases new data on DMD drug ahead of earnings - MSN
Dimensional Fund Advisors LP Has $12.96 Million Stock Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO Inc. (NASDAQ:RGNX) Shares Acquired by Squarepoint Ops LLC - MarketBeat
Selling Buzz: Regenxbio Inc [RGNX] Director KARABELAS ARGERIS N sells 10,000 shares of the company - Knox Daily
A Tale of Resilience: Regenxbio Inc Amid Stock Market Turbulence - The InvestChronicle
Regenxbio director Karabelas sells $101,052 in stock By Investing.com - Investing.com Australia
REGENXBIO Inc. (NASDAQ:RGNX) Director Argeris N. Karabelas Sells 10,000 Shares - Defense World
Learn to Evaluate (RGNX) using the Charts - Stock Traders Daily
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference - cnhinews.com
Recent Insider Activity Could Benefit Regenxbio Inc (RGNX) - Knox Daily
Can you still get a good price for Regenxbio Inc (RGNX) Shares at this point? - US Post News
Stock Surge: Regenxbio Inc (RGNX) Closes at 10.49, Marking a -2.87 Increase/Decrease - The Dwinnex
Cubist Systematic Strategies LLC Buys 79,655 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
RGNX stock touches 52-week low at $10.48 amid market challenges - Investing.com Australia
RGNX stock touches 52-week low at $10.48 amid market challenges By Investing.com - Investing.com South Africa
REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
A company insider recently sold 10,000 shares of Regenxbio Inc [RGNX]. Should You Sale? - Knox Daily
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regenxbio Inc Stock (RGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Sale |
10.11 |
10,000 |
101,052 |
11,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Sale |
11.56 |
10,000 |
115,588 |
11,286 |
| Mills Kenneth T. | Director |
Aug 08 '24 |
Option Exercise |
0.85 |
36,316 |
30,869 |
444,351 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Option Exercise |
3.85 |
10,100 |
38,874 |
21,386 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Sale |
13.51 |
10,100 |
136,454 |
11,286 |
| Simpson Curran | Chief Executive Officer |
Aug 01 '24 |
Sale |
15.00 |
100 |
1,500 |
170,037 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):